Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02652832

Acronym

Plasti-Stim

Enrollment

165

Registered

2016-01-12

Start date

2010-12-01

Completion date

2017-10-11

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Schizophrenia

Brief summary

The aim of this study is to investigate the effects of non invasive brain stimulation - NIBS - techniques (Electroconvulsivotherapy - ECT, transcranial Direct Current Stimulation - tDCS, repetitive transcranial magnetic stimulation - rTMS) on serum Brain Derived Neurotrophic factor (BDNF) levels in patients with depression and schizophrenia. Four blood samples will be collected in each participants, one before the NIBS sessions, and 3 after the completion of NIBS protocols: one immediately after the end of the NIBS sessions, a second one week after and a last one month after. Two blood samples separated by one month will also be collected in a a group of healthy volunteers.

Detailed description

The hypothesis is that NIBS will modulate BDNF levels and that the modification in serum BDNF levels will be correlated with clinical improvements in the sample of patients.

Interventions

DEVICEnon invasive brain stimulation

non invasive brain stimulation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* in the depression group: DSM IV criteria of MDD; HDRS17\> 22; stage 2 of resistance; received rTMS or ECT * in the schizophrenia group DSM IV criteria of schizophrenia; pharmaco-resistance of symptoms (either negative symptoms or auditory verbal hallucination); received rTMS or tDCS * in the healthy volunteers group : to not have axis I of DSM IV diagnosis; no siblings with axis I DSM IV diagnosis

Exclusion criteria

* less than 18 years old * pregnancy * received benzodiazepine In the depression and schizophrenia group: * bipolar disorder * other axis I of DSM IV diagnosis (excluding for Tobacco use disorder)

Design outcomes

Primary

Measure	Time frame
serum BDNF levels	from baseline to one month

Countries

France

Contacts

STUDY_DIRECTORjerome brunelin, PhD

CH le vinatier

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026